Showing 5511-5520 of 9529 results for "".
- Cutera Rolls Out Heroes Among Us Programhttps://practicaldermatology.com/news/cutera-rolls-out-heroes-among-us-program/2460228/Cutera is launching its new “Heroes Among Us” program to showcase patients who’ve been positively affected by Cutera technologies. The new program was launched at the Cutera University Clinical Forum (CUCF) in Scott
- CBD Brands Initiates AD studyhttps://practicaldermatology.com/news/cbd-brands-initiates-ad-study-1/2460226/In the wake of the US Food and Drug Administration’s (FDA) recent revised warning about the risks of CBD products, CBD Brands is initiating a study to investigate a novel cannabidiol lotion for the treatment of atopic dermatitis (AD). The study aims to provide a preliminary assess
- Baring Private Equity Asia Agrees to Acquire Lumenishttps://practicaldermatology.com/news/baring-private-equity-asia-agrees-to-acquire-lumenis-1/2460222/Baring Private Equity Asia’s affiliated private equity funds are acquiring Lumenis. The transaction, which values Lumenis at an enterprise value of more than $1 billion, remains subject to the customary regulatory approval process. It is expected to be completed in early 2020. <
- Citing Underperformance, Hologic Sells Cynosure Medical Aesthetics Business for $205Mhttps://practicaldermatology.com/news/hologic-to-sell-cynosure-medical-aesthetics-business-for-205m/2460221/Hologic is selling Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. This is a tenth of the $1.6B that Hologic, a women's&n
- Melanoma Rates Drop Sharply Among Teens, Young Adultshttps://practicaldermatology.com/news/melanoma-rates-drop-sharply-among-teens-young-adults/2460217/Cases of melanoma among U.S. adolescents and young adults declined markedly from 2006 to 2015 - even as the skin cancer's incidence continued to increase among older adults and the general population during the span, new research in JAMA Dermatology shows. The finding,
- Allergan Pays Exicure $25M upfront in Collaboration Deal to Develop Hair Loss Treatmenthttps://practicaldermatology.com/news/allergan-pays-exicure-25m-upfront-in-collaboration-deal-to-develop-hair-loss-treatment/2460216/Allergan Pharmaceuticals International Limited has entered into a global collaboration agreement with Exicure to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. Allergan will receive exclusive access and options to licen
- Cassiopea Enrolls First Patient in Phase II Trial of Clascoterone Solution for the Treatment of Androgenetic Alopecia in Femaleshttps://practicaldermatology.com/news/cassiopea-enrolls-first-patient-in-phase-ii-trial-of-clascoterone-solution-for-the-treatment-of-androgenetic-alopecia-in-females/2460215/After receiving approval from the German Authority BfArM and the coordinating ethical committee, Cassiopea SpA is now enrolling the first patient in a Phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia (AGA) in fema
- Post-Market Price Changes Alone Account for Most Recent Spending Growth for Biologics, and Rebates Have Little Impacthttps://practicaldermatology.com/news/post-market-price-changes-alone-account-for-most-recent-spending-growth-for-biologics-and-rebates-have-little-impact/2460214/Annual spending on biologics by U.S. public programs and beneficiaries nearly doubled from 2012 to 2016, according to research presented
- Psoriasis Onset Determines if Psoriatic Arthritis Patients Develop Arthritis or Psoriasis Firsthttps://practicaldermatology.com/news/psoriasis-onset-determines-if-psoriatic-arthritis-patients-develop-arthritis-or-psoriasis-first/2460212/Age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis., finds a new study presented at the 2019 ACR/ARP Annual Meeting in Atlanta. Additionally, pustular psoriasis is associated with arthritis onset two years earlier than the in
- FDA Accepts NDA for Cassiopea's Clascoterone Cream 1% for Acnehttps://practicaldermatology.com/news/fda-accepts-nda-for-cassiopeas-clascoterone-cream-1-for-acne-1/2460209/The FDA has accepted Cassiopea SpA's New Drug Application (NDA) for clascoterone cream 1% for review. Cassiopea, a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological con